Current concepts of metastasis in melanoma

Expert Review of Dermatology

Volumn 3, Issue 5, 2008, Pages 569-585

  Zbytek, Blazej ^a   Carlson, J Andrew ^b   Granese, Jacqueline ^a   Ross, Jeffrey ^b   Mihm Jr , Martin ^c   Slominski, Andrzej ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b ALBANY MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Biotherapy; Chemokine; Integrin; Melanoma; Metastasis; Syntenil lymp node

Indexed keywords

ALPHA2B INTERFERON; B RAF KINASE; CARBOPLATIN; CELL ADHESION MOLECULE; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; GROWTH FACTOR; INTERLEUKIN 2; IPILIMUMAB; MATRIX METALLOPROTEINASE; MELANIN; MELPHALAN; MIDOSTAURIN; MONOCLONAL ANTIBODY LM 609; OBLIMERSEN; PACLITAXEL; PENICILLAMINE; PHENYLTHIOUREA; PKC 412A; PROTEINASE ACTIVATED RECEPTOR; RAS PROTEIN; SORAFENIB; TICILIMUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANGIOGENESIS; BONE MARROW; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSTIC VALUE; DISTANT METASTASIS; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; EMBOLISM; EXTRAVASATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; IN-TRANSIT METASTASIS; LUNG METASTASIS; LYMPH FLOW; LYMPHADENECTOMY; MELANOCYTE; MELANOGENESIS; MELANOMA; MELANOMA CELL; METASTASIS; MONOTHERAPY; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; REGIONAL METASTASIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SATELLITE METASTASIS; SENTINEL LYMPH NODE BIOPSY; SKIN CARCINOGENESIS; SKIN METASTASIS; SYSTEMIC CIRCULATION;

EID: 55249095322     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/17469872.3.5.569     Document Type: Review

References (164)

1. Balch CM, Soong SJ, Atkins MB et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J. Clin. 54(3), 131-149 (2004).
2. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 19(16), 3635-3648 (2001).
3. Bastian BC, Kashani-Sabet M, Hamm H et al. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res. 60(7), 1968-1973 (2000).
4. North JP, Kageshita T, Pinkel D, Leboit PE, Bastian BC. Distribution and significance of occult intraepidermal tumor cells surrounding primary melanoma. J. Invest. Dermatol. 128(8), 2024-2030 (2008).
5. Xu X, Gimotty PA, Guerry D et al. Lymphatic invasion revealed by multispectral imaging is common in primary melanomas and associates with prognosis. Hum. Pathol. 39(6), 901-909 (2008).
6. Dadras SS, Lange-Asschenfeldt B, Velasco P et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod. Pathol. 18(9), 1232-1242 (2005).
7. Dadras SS, Paul T, Bertoncini J et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am. J. Pathol. 162(6), 1951-1960 (2003).
8. Morton DL, Thompson JF, Cochran AJ et al. Sentinel-node biopsy or nodal observation in melanoma. N. Engl. J. Med. 355(13), 1307-1317 (2006).
9. Cochran AJ, Ohsie SJ, Binder SW. Pathobiology of the sentinel node. Curr. Opin Oncol. 20(2), 190-195 (2008).
10. Mocellin S, Hoon DS, Pilati P, Rossi CR, Nitti D. Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis of prognosis. J. Clin. Oncol. 25 (12), 1588-1595 (2007).
11. Fincher TR, McCarty TM, Fisher TL et al. Patterns of recurrence after sentinel lymph node biopsy for cutaneous melanoma. Am. J. Surg. 186(6), 675-681 (2003).
12. Denninghoff VC, Falco J, Kahn AG, Trouchot V, Curutchet HP, Elsner B. Sentinel node in melanoma patients: triple negativity with routine techniques and PCR as positive prognostic factor for survival. Mod. Pathol. 21(4), 438-444 (2008).
13. Soikkeli J, Lukk M, Nummela P et al. Systematic search for the best gene expression markers for melanoma micrometastasis detection. J. Pathol. 213(2), 180-189 (2007).
14. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br. J. Cancer 90 (10), 1877-1881 (2004).
15. Ikeda H, Lethe B, Lehmann F et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6(2), 199-208 (1997).
16. Li Q, Murphy M, Ross J, Sheehan C, Carlson JA. Skp2 and p27kipl expression in melanocytic nevi and melanoma: an inverse relationship. J. Cutan. Pathol. 31(10), 633-642 (2004).
17. Torisu-Itakura H, Lee JH, Scheri RP et al. Molecular characterization of inflammatory genes in sentinel and nonsentinel nodes in melanoma. Clin. Cancer Res. 13 (11), 3125-3132 (2007).
18. Sarff M, Edwards D, Dhungel B et al. OX40 (CD134) expression in sentinel lymph nodes correlates with prognostic features of primary melanomas. Am. J. Surg. 195 (5), 621-625 (2008).
19. + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J. Clin. Oncol. 24(7), 1169-1177 (2006).
20. Polak ME, Borthwick NJ, Gabriel FG et al. Mechanisms of local immunosuppression in cutaneous melanoma. Br. J. Cancer 96(12), 1879-1887 (2007).
21. Carlson JA, Slominski A, Linette GP, Mihm MC Jr, Ross JS. Biomarkers in melanoma: staging, prognosis and detection of early metastases. Expert Rev. Mol. Diagn. 3(3), 303-330 (2003).
22. Palmieri G, Casula M, Sini MC, Ascierto PA, Cossu A. Issues affecting molecular staging in the management of patients with melanoma. J. Cell. Mol. Med. 11 (5), 1052-1068 (2007).
23. Slominski A, Wortsman J, Carlson JA, Matsuoka LY, Balch CM, Mihm MC. Malignant melanoma. Arch. Pathol. Lab. Med. 125(10), 1295-1306 (2001).
24. Carlson JA, Ross JS, Slominski A et al. Molecular diagnostics in melanoma. J. Am. Acad. Dermatol. 52(5), 743-775; quiz 775-748 (2005).
25. Visus C, Andres R, Mayordomo JI et al. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma. Melanoma Res. 17(2), 83-89 (2007).
26. Arenberger P, Arenbergerova M, Vohradnikova O, Kremen J. Early detection of melanoma progression by quantitative real-time RT-PCR analysis for multiple melanoma markers. Keio J. Med. 57(1), 57-64 (2008).
27. Xi L, Nicastri DG, El-Hefnawy T, Hughes SJ, Luketich JD, Godfrey TE. Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Clin. Chem. 53(7), 1206-1215 (2007)
28. Tveito S, Maelandsmo GM, Hoifodt HK, Rasmussen H, Fodscad O. Specific isolation of disseminated cancer cells: a new method permitting sensitive detection of target molecules of diagnostic and therapeutic value. Clin. Exp. Metastasis 24(5), 317-327 (2007).
29. Liotta LA, Saidel MG, Kleinerman J. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res. 36(3), 889-894 (1976).
30. Faries MB, Gupta RK, Ye X et al. A comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients. Cancer Invest. 25(5), 285-293 (2007).
31. Domingo-Domenech J, Castel T, Auge JM et al. Prognostic implications of protein S-100β serum levels in the clinical outcome of high-risk melanoma patients. Tumour Biol. 28(5), 264-272 (2007).
32. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma. Med. Oncol. DOI: 10.1007/sl2032-008-9058-y (2008) (Epub ahead of print).
33. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res. 16(5), 405-411 (2006).
34. Bolarider A, Wagenius G, Larsson A et al. The role of circulating angiogenic factors in patients operated on for localized malignant melanoma, Anticancer Res. 27(5A), 3211-3217 (2007).
35. Mian S, Ugurel S, Parkinson E et al. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J. Clin. Oncol. 23(22), 5088-5093 (2005).
36. Som P, Atkins HL, Bandoypadhyay D et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J. Nucl. Med. 21(7), 670-675 (1980).
37. Prichard RS, Hill AD, Skehan SJ, O'Higgins NJ. Positron emission tomography for staging and management of malignant melanoma. Br. J. Surg. 89(4), 389-396 (2002).
38. Strobel K, Dummer R, Husarik DB, Perez Lago M, Hany TF, Steinert HC. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology 244(2), 566-574 (2007).
39. Crean AM, Juli C. Diagnosis of metastatic melanoma to the heart with an intrinsic contrast approach using melanin inversion recovery imaging. J. Comput. Assist. Tomogr. 31(6), 924-930 (2007).
40. Miao, Y, Figueroa SD, Fisher DR et al. 203Pb-labeled {α}-melanocyte-stimulating hormone peptide as an imaging probe for melanoma detection. J. Nucl. Med. 49 (5), 823-829 (2008).
41. 111In-labeled α-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J. Nucl. Med. 48 (1), 73-80 (2007).
42. Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat. Rev. Genet. 8(5), 341-352 (2007).
43. Gaggioli C, Sahai E. Melanoma invasion - current knowledge and future directions. Pigment Cell Res. 20 (3), 161-172 (2007).
44. Crowson AN, Magro, C, Miller A, Mihm MC, Jr. The molecular basis of melanomagenesis and the metastatic phenotype. Semin. Oncol. 34(6), 476-490 (2007).
45. Sabatino M, Zhao Y, Voiculescu S et al. Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis. Cancer Res. 68(1), 122-131 (2008).
46. Grichnik JM, Burch JA, Schulteis RD et al. Melanoma, a tumor based on a mutant stem cell? J. Invest. Dermatol. 126(1), 142-153 (2006).
47. Wang E, Voiculescu S, Le Poole IC et al. Clonal persistence and evolution during a decade of recurrent melanoma. J. Invest. Dermatol. 126(6), 1372-1377 (2006).
48. Pawelek JM, Chakraborty AK. Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis. Nat. Rev. Cancer 8(5), 377-386 (2008).
49. Pawelek JM, Chakraborty AK, Rachkovsky ML, Orlow SJ, Bolognia JL, Sodi SA. Altered N-glycosylation in macrophage x melanoma fusion hybrids. Cell. Mol. Biol. (Noisy-le-grand) 45(7), 1011-1027 (1999).
50. Meier F, Will S, Ellwanger U et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br. J. Dermatol. 147(1), 62-70 (2002).
51. Markowitz JS, Cosimi LA, Carey RW et al. Prognosis after initial recurrence of cutaneous melanoma. Arch. Surg. 126(6), 703-707 (1991).
52. Reintgen DS, Cox C, Slingluff CL Jr, Seigler HF. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann. Plast. Surg. 28(1), 45-49 (1992).
53. Soong SJ, Harrison RA, McCarthy WH, Urisi MM, Balch CM. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J. Surg. Oncol. 67(4), 228-233 (1998).
54. Nathanson SD. Insights into the mechanisms of lymph node metastasis. Cancer 98(2), 413-423 (2003).
55. Saharinen P, Tammela T, Karkkainen MJ, Alitalo K. Lymphatic vasculature: development, molecular regulation and role in rumor metastasis and inflammation. Trends Immunol. 25(7), 387-395 (2004).
56. Skobe M, Hamberg LM, Hawighorst T et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am. J. Pathol. 159(3), 893-903 (2001).
57. Sini P, Samarzija I, Baffert F et al. Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics. Cancer Res. 68(5), 1581-1592 (2008).
58. Vihinen PP, Hilli J, Vuoristo MS, Syrjanen KJ, Kahari VM, Pyrhonen SO. Serum VEGF-C is associated with metastatic site in patients with malignant melanoma. Acta Oncol. 46(5), 678-684 (2007).
59. Wobser M, Siedel C, Schrama D, Brocker EB, Becker JC, Vetter-Kauczok CS. Expression pattern of the lymphatic and vascular markers VEGFR-3 and CD31 does not predict regional lymph node metastasis in cutaneous melanoma. Arch. Dermatol. Res. 297(8), 352-357 (2006).
60. Payne AS, Cornelius LA. The role of chemokines in melanoma tumor growth and metastasis. J. Invest. Dermatol. 118(6), 915-922 (2002).
61. Takeuchi H, Fujimoto A, Tanaka M, Yamano T, Hsueh E, Hoon DS. CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin. Cancer Res. 10(7), 2351-2358 (2004).
62. Scala S, Ottaiano A, Ascierto PA et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin. Cancer Res. 11(5), 1835-1841 (2005).
63. Ben-Baruch A. Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin. Exp. Metastasis 25(4), 345-356 (2008).
64. Hieken TJ, Ronan SG, Farolan M, Shilkaitis AL, Das Gupta TK. Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma. Cancer 85(2), 375-382 (1999).
65. 1 integrin expression: a marker of lymphatic metastases in cutaneous malignant melanoma. Anticancer Res. 16(4B), 2321-2324 (1996).
66. Marchetti D, Murry B, Galjour J, Wilke-Greiter A. Human melanoma TrkC: its association with a purine-analog-sensitive kinase activity. J. Cell. Biochem. 88(5), 865-872 (2003).
67. Marchetti D, Aucoin R, Blust J, Murry B, Greiter-Wilke A. p75 neurotrophin receptor functions as a survival receptor in brain-metastatic melanoma cells. J. Cell. Biochem. 91(1), 206-215 (2004).
68. Denkins Y, Reiland J, Roy M et al. Brain metastases in melanoma: roles of neurotrophins. Neuro. Oncol. 6(2), 154-165 (2004).
69. Walch ET, Albino AP, Marchetti D. Correlation of overexpression of the low-affinity p75 neurotrophin receptor with augmented invasion and heparanase production in human malignant melanoma cells. Int. J. Cancer 82(1), 112-120 (1999).
70. Axelsen JB, Lotem J, Sachs L, Domany E. Genes overexpressed in different human solid cancers exhibit different tissue-specific expression profiles. Proc. Natl Acad. Sci. USA 104(32), 13122-13127 (2007).
71. Carrell E, Kelly C, Middleton MR. Brain metastases in melanoma: a European perspective. Semin. Oncol. 29(5), 513-517 (2002).
72. Abeloff MD. Clinical Oncology. Elsevier Churchill Livingstone, PA, USA (2004).
73. Neuman HB, Patel A, Hanlon C, Wolchok JD, Houghton AN, Coit DG. Stage-IV melanoma and pulmonary metastases: factors predictive of survival. Ann. Surg. Oncol. 14(10), 2847-2853 (2007).
74. Chen YM, Wang PS, Liu JM et al. Effect of age on pulmonary metastases and immunotherapy in young and middle-aged mice. J. Chin. Med. Assoc. 70(3), 94-102 (2007).
75. Carlson JA. Tumor doubling time of cutaneous melanoma and its metastasis. Am. J. Dermatopathol. 25(4), 291-299 (2003).
76. Ollila DW, Stern SL, Morton DL. Tumor doubling time: a selection factor for pulmonary resection of metastatic melanoma. J. Surg. Oncol. 69(4), 206-211 (1998).
77. Lorigan JG, Wallace S, Mavligit GM. The prevalence and location of metastases from ocular melanoma: imaging study in 110 patients. Am. J. Roentgenol. 157(6), 1279-1281 (1991).
78. Bakalian S, Marshall JC, Logan P et al. Molecular pathways mediating liver metastasis in patients with uveal melanoma. Clin. Cancer Res. 14(4), 951-956 (2008).
79. Agrawal S, Yao TJ, Coit DG. Surgery for melanoma metastatic to the gastrointestinal tract. Ann. Surg. Oncol. 6(4), 336-344 (1999).
80. Amersi FF, Terando AM, Goto Y et al. Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin. Cancer Res. 14(3), 638-645 (2008).
81. Bedogni B, Welford SM, Cassarino DS, Nickoloff BJ, Giaccia AJ, Powell MB. The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell 8(6), 443-454 (2005).
82. Postovit LM, Seftor EA, Seftor RE, Hendrix MJ. Influence of the microenvironment on melanoma cell fate determination and phenotype. Cancer Res. 66(16), 7833-7836 (2006).
83. Schutyser E, Su Y, Yu Y et al. Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells. Eur. Cytokine Netw. 18(2), 59-70 (2007).
84. Sun B, Zhang S, Zhang D, Gu Y, Zhang W, Zhao X. The influence of different microenvironments on melanoma invasiveness and microcirculation patterns: an animal experiment study in the mouse model. J. Cancer Res. Clin. Oncol. 133(12), 979-985 (2007).
85. Salgado KB, Toscani NV, Silva LL, Hilbig A, Barbosa-Coutinho LM. Immunoexpression of endoglin in brain metastasis secondary to malignant melanoma: evaluation of angiogenesis and comparison with brain metastasis secondary to breast and lung carcinomas. Clin. Exp. Metastasis 24(6), 403-410 (2007).
86. Bayer-Garner IB, Hough AJ Jr, Smoller BR. Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness. Mod. Pathol. 12(8), 770-774 (1999).
87. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med. 77(7), 527-543 (1999).
88. Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ. Diabetic retinopathy is associated with a switch in splicing from anti- to pro- angiogenic isoforms ofvascular endothelial growth factor. Diabetologia 48(11), 2422-2427 (2005).
89. Woolard J, Wang WY, Bevan HS et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64(21), 7822-7835 (2004).
90. Pritchard-Jones RO, Dunn DB, Qiu Y et al. Expression of VEGF (xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma. Br. J. Cancer. 97(2), 223-230 (2007).
91. Liang S, Slattery MJ, Wagner D, Simon SI, Dong C. Hydrodynamic shear rate regulates melanoma-leukocyte aggregation, melanoma adhesion to the endothelium, and subsequent extravasation. Ann. Biomed. Eng. 36(4), 661-671 (2008).
92. Liang S, Sharma A, Peng HH, Robertson G, Dong C. Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. Cancer Res. 67(12), 5814-5820 (2007).
93. Brose MS, Volpe P, Feldman M et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62(23), 6997-7000 (2002).
94. 1 (VLA- 4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers. J. Cell. Physiol. 212(2), 368-374 (2007).
95. Fens MH, Mastrobattista E, de Graaff AM et al. Angiogenic endothelium shows lactadherin-dependent phagocytosis of aged erythrocytes and apoptotic cells. Blood 111(9), 4542-4550 (2008).
96. Komatsu N, Waki M, Sue M et al. Heparanase expression in B16 melanoma cells and peripheral blood neutrophils before and after extravasation detected by novel anti-mouse heparanase monoclonal antibodies. J. Immunol. Methods 331(1-2), 82-93 (2008).
97. Seftor RE, Seftor EA, Koshikawa N et al. Cooperative interactions of laminin 5 γ2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res. 61(17), 6322-6327 (2001).
98. Quintanilla-Dieck MJ, Codriansky K, Keady M, Bhawan J, Runger TM. Cathepsin K in melanoma invasion. J. Invest. Dermatol. 128(9), 2281-2288 (2008).
99. Frohlich E, Schlagenhauff B, Mohrle M, Weber E, Klessen C, Rassner G. Activity, expression, and transcription rate of the cathepsins B, D, H, and L in cutaneous malignant melanoma. Cancer 91(5), 972-982 (2001).
100. Pocza P, Suli-Vargha H, Darvas Z, Falus A. Locally generated VGVAPG and VAPG elastin-derived peptides amplify melanoma invasion via the galectin-3 receptor. Int. J. Cancer 122(9), 1972-1980 (2008).
101. Lacal PM, Ruffini F, Pagani E, D'Arri S. An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells. Int. J. Oncol. 27(6), 1625-1632 (2005).
102. Zhou Y, Dai DL, Martinka M et al. Osteopontin expression correlates with melanoma invasion. J. Invest. Dermatol. 124(5), 1044-1052 (2005).
103. Philip S, Bulbule A, Kundu GC. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-Κ B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J. Biol. Chem. 276(48), 44926-44935 (2001).
104. Rangel J, Nosrati M, Torabian S et al. Osteopontin as a molecular prognostic marker for melanoma. Cancer 112(1), 144-150 (2008).
105. Fuertes MB, Girart MV, Molinero, LL et al. Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J. Immunol. 180(7), 4606-4614 (2008).
106. Lacreusette A, Nguyen JM, Pandolfino MC et al. Loss of oncostatin M receptor β in metastatic melanoma cells. Oncogene 26(6), 881-892 (2007).
107. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293(6), 715-722 (2005).
108. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Pictures in molecular medicine: three-dimensional visualization of intravascular tumor cells in mice. Trends Mol. Med. 7(8), 377 (2001).
109. Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 59(6), 1295-1300 (1999).
110. Bruggemann LW, Versteeg HH, Niers TM, Reitsma PH, Spek CA. Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders. J. Cell Mol. Med. DOI: 10.1111/j.1582-4934.2008.00316.x (2008) (Epub ahead of print).
111. Depasquale I, Thompson WD. Prognosis in human melanoma: PAR-1 expression is superior to other coagulation components and VEGF. Histopathology 52(4), 500-509 (2008).
112. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 407(6801), 258-264 (2000).
113. Bergmeier W, Piffath CL, Goerge T et al. The role of platelet adhesion receptor GPIbα far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc. Natl Acad. Sci. USA 103(45), 16900-16905 (2006).
114. Jain S, Zuka M, Liu J et al. Platelet glycoprotein Ib α supports experimental lung metastasis. Proc. Natl Acad. Sci. USA 104(21), 9024-9028 (2007).
115. Eslin DE, Zhang C, Samuels KJ et al. Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin. Blood 104(10), 3173-3180 (2004).
116. Struyf S, Burdick MD, Peeters E et al. Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res. 67(12), 5940-5948 (2007).
117. Lugassy C, Barnhill RL. Angiotropic melanoma and extravascular migratory metastasis: a review. Adv. Anat. Pathol. 14(3), 195-201 (2007).
118. Lugassy C, Eyden BP, Christensen L, Escande JP. Angio-tumoral complex in human malignant melanoma characterised by free laminin: ultrastructural and immunohistochemical observations. J. Submicrosc. Cytol. Pathol. 29(1), 19-28 (1997).
119. Kuratomi Y, Nomizu M, Tanaka K et al. Laminin γ 1 chain peptide, C-16 (KAFDITYVRLKF), promotes migration, MMP-9 secretion, and pulmonary metastasis of B16-F10 mouse melanoma cells. Br. J. Cancer 86(7), 1169-1173 (2002).
120. Gupta PB, Kuperwasser C, Brunet JP et al. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat. Genet. 37(10), 1047-1054 (2005).
121. Topczewska JM, Postovit LM, Margaryan NV et al. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat. Med. 12(8), 925-932 (2006).
122. Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocr. Rev. 21(5), 457-487 (2000).
123. Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol. Rev. 84(4), 1155-1228 (2004).
124. Slominski A, Paus R, Mihm MC. Inhibition of melanogenesis as an adjuvant strategy in the treatment of melanotic melanomas: selective review and hypothesis. Anticancer Res. 18(5B), 3709-3715 (1998).
125. Slominski A, Zbytek B, Slominski R. Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells. Int. J. Cancer (2008) (In press).
126. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer 109(3), 455-464 (2007).
127. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 445(7130), 851-857 (2007).
128. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64(19), 7099-7109 (2004).
129. Eisen T, Ahmad T, Flaherty KT et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer. 95(5), 581-586 (2006).
130. Flaherty KT, Brose, M., Schucter, L. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates antitumor activity in the expansion cohort of patients with metastatic melanoma. J. Clin. Oncol. 22(Suppl.), 14S (2004).
131. McDermott DF, Sosman JA, Gonzalez R et al. Double-blind randomized Phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J. Clin. Oncol. 26(13), 2178-2185 (2008).
132. 2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin. Cancer Res. 13(6), 1801-1809 (2007).
133. Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother. Pharmacol. 61(4), 535-548 (2008).
134. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 110(12), 2614-2627 (2007).
135. Maker AV, Yang JC, Sherry RM et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J. Immunother. 29(4), 455-463 (2006).
136. Downey SG, Klapper JA, Smith FO et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin. Cancer Res. 13(22 Pt 1), 6681-6688 (2007).
137. Maker AV, Phan GQ, Attia P et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a Phase I/II study. Ann. Surg. Oncol. 12(12), 1005-1016 (2005).
138. Mohammad R, Giri A, Goustin AS. Small-molecule inhibitors of Bcl-2 family proteins as therapeutic agents in cancer. Recent Patents Anticancer Drug Discov. 3(1), 20-30 (2008).
139. Bedikian AY, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol. 24(29), 4738-4745 (2006).
140. Kuphal S, Bauer R, Bosserhoff AK. Integrin signaling in malignant melanoma. Cancer Metastasis Rev. 24(2), 195-222 (2005).
141. Hersey P, Sosman J, O'Day S. A Phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human metastatic melanoma (MM). Proc. Am. Soc. Clin. Oncol. 23, 711S (2005).
142. Pashenkov M, Goess G, Wagner C et al. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J. Clin. Oncol. 24(36), 5716-5724 (2006).
143. Millward MJ, House C, Bowtell D et al. The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a Phase IIA clinical and biologic study. Br. J. Cancer. 95(7), 829-834 (2006).
144. Pavco PA, Bouhana KS, Gallegos AM et al. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin. Cancer Res. 6(5), 2094-2103 (2000).
145. Weng DE, Masci PA, Radka SF et al. A Phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors. Mol. Cancer Ther. 4(6), 948-955 (2005).
146. Reichle A, Vogt T, Coras B et al. Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized Phase II trial. Melanoma Res. 17(6), 360-364 (2007).
147. Carlson JA, Linette GP, Aplin A, Ng B, Slominski A. Melanocyte receptors: clinical implications and therapeutic relevance. Dermatol. Clin. 25(4), 541-557, viii-ix (2007).
148. Slominski A, Wortsman J, Tuckey RC, Paus R. Differential expression of HPA axis homolog in the skin. Mol. Cell. Endocrinol. 265-266, 143-149 (2007).
149. Slominski A. Coming of age of melanogenesis-related proteins. Arch. Pathol. Lab. Med. 126(7), 775-777 (2002).
150. 17Lu-labeled DOTA conjugated (α-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model. Cancer Biother. Radiopharm. 22(3), 333-341 (2007).
151. Slominski A, Zbytek B, Semak I, Sweatman T, Wortsman J. CRH stimulates POMC activity and corticosterone production in dermal fibroblasts. J. Neuroimmunol. 162(1-2), 97-102 (2005).
152. Slominski A, Wortsman J, Luger T, Paus R, Solomon S. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiolog. Rev. 80(3), 979-1020 (2000).
153. Slominski A, Zbytek B, Pisarchik A, Slominski RM, Zmijewski MA, Wortsman J. CRH functions as a growth factor/cytokine in the skin. J. Cell. Physiol. 206(3), 780-791 (2006).
154. Carlson KW, Nawy SS, Wei ET et al. Inhibition of mouse melanoma cell proliferation by corticotropin-releasing hormone and its analogs. Anticancer Res. 21(2A), 1173-1179 (2001).
155. Slominski A, Gomez-Sanchez CE, Foecking MF, Wortsman J. Metabolism of progesterone to DOC, corticosterone and 18OHDOC in cultured human melanoma cells. FEBS Lett. 455(3), 364-366 (1999).
156. Slominski A, Zbytek B, Szczesniewski A et al. CRH stimulation of corticosteroids production in melanocytes is mediated by ACTH. Am. J. Physiol. 288(4), E701-E706 (2005).
157. Slominski A, Zjawiony J, Wortsman J et al. A novel pathway for sequential transformation of 7-dehydrocholesterol and expression of the P450scc system in mammalian skin. Eur. J. Biochem. 271(21), 4178-4188 (2004).
158. Slominski A, Zjawiony J, Paus R, Elias PM, Tobin DJ, Feingold K. Skin as an endocrine organ: implications for its function. Drug. Discov. Today Dis. Mech. (2008) (In press).
159. Slominski A TD, Zmijewski M, Wortsman J, Paus R. Cutaneous melatonin: production, metabolism and phenotypic effects. Trends End. Metab. 19, 17-24 (2008).
160. Karakousis CP, Velez A, Driscoll DL, Takita H. Metastasectomy in malignant melanoma. Surgery 115(3), 295-302 (1994).
161. Byrne TN, Cascino TL, Posner JB. Brain metastasis from melanoma. J. Neurooncol. 1(4), 313-317 (1983).
162. Lugassy C, Barnhill RL. Angiotropic melanoma and extravascular migratory metastasis: a review. Adv. Anat. Pathol. 14(3), 195-201 (2007).
163. Van Es SL, Colman M, Thompson JF, McCarthy SW, Scolyer R.A. Angiotropism is an independent predictor of local recurrence and in-transit metastasis in primary cutaneous melanoma. Am. J. Surg. Pathol. 32(9), 1396-403 (2008).
164. Vlaykova T, Talve L, Hahka-Kemppinen M et al. Immunohistochemically detectable bcl-2 expression in metastatic melanoma: association with survival and treatment response. Oncology 62(3), 259-268 (2002).